Ernexa Therapeutics Inc. Increase (Decrease) in Other Receivables
Ernexa Therapeutics Inc. (ERNA) reported Increase (Decrease) in Other Receivables of -$12.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-06
- Ernexa Therapeutics Inc. increase (decrease) in other receivables for the quarter ending 2025-12-31 was -$58.00K, a 123.20% decline year-over-year.
- Ernexa Therapeutics Inc. increase (decrease) in other receivables for the quarter ending 2025-09-30 was -$1.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other receivables for the quarter ending 2025-06-30 was -$2.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other receivables for the quarter ending 2025-03-31 was -$281.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other receivables for fiscal 2025 was -$342.00K, a 2950.00% decline from fiscal 2024.
- Ernexa Therapeutics Inc. increase (decrease) in other receivables for fiscal 2024 was $12.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other receivables for fiscal 2023 was -$527.00K, a 301.15% decline from fiscal 2022.
- Ernexa Therapeutics Inc. increase (decrease) in other receivables for fiscal 2022 was $262.00K, a 60.24% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$59.00K derived: sum of 2 quarters · filed 2026-03-13 | -$61.00K derived: sum of 3 quarters · filed 2026-08-06 | -$342.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$3.00K derived: sum of 2 quarters · filed 2026-08-06 | -$284.00K 10-Q · filed 2025-11-07 | -$34.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$283.00K 10-Q · filed 2026-08-06 | -$33.00K derived: sum of 3 quarters · filed 2026-08-06 | -$74.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$281.00K 10-Q · filed 2026-05-11 | -$31.00K derived: sum of 2 quarters · filed 2026-05-11 | -$72.00K derived: sum of 3 quarters · filed 2026-05-11 | -$195.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $209.00K derived: sum of 2 quarters · filed 2026-03-13 | $86.00K derived: sum of 3 quarters · filed 2026-03-13 | $12.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$164.00K derived: sum of 2 quarters · filed 2025-11-07 | -$238.00K 10-Q · filed 2025-11-07 | -$1.59M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$197.00K 10-Q · filed 2025-08-13 | -$1.55M derived: sum of 3 quarters · filed 2025-08-13 | -$757.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$74.00K 10-Q · filed 2025-05-07 | -$1.43M derived: sum of 2 quarters · filed 2025-05-07 | -$634.00K derived: sum of 3 quarters · filed 2025-05-07 | -$297.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$560.00K derived: sum of 2 quarters · filed 2025-03-12 | -$223.00K derived: sum of 3 quarters · filed 2025-03-12 | -$527.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $792.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.13M derived: sum of 2 quarters · filed 2024-11-12 | $825.00K 10-Q · filed 2024-11-12 | $850.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $337.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $33.00K 10-Q · filed 2024-08-13 | $58.00K derived: sum of 3 quarters · filed 2024-08-13 | $290.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$304.00K 10-Q · filed 2024-05-14 | -$279.00K derived: sum of 2 quarters · filed 2024-05-14 | -$47.00K derived: sum of 3 quarters · filed 2024-05-14 | -$188.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $257.00K derived: sum of 2 quarters · filed 2024-03-14 | $116.00K derived: sum of 3 quarters · filed 2024-03-14 | $262.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $232.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $91.00K derived: sum of 2 quarters · filed 2023-11-13 | $237.00K 10-Q · filed 2023-11-13 | $901.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $5.00K 10-Q · filed 2023-08-11 | $669.00K derived: sum of 3 quarters · filed 2023-08-11 | $669.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $146.00K 10-Q · filed 2023-05-11 | $810.00K derived: sum of 2 quarters · filed 2023-05-11 | $810.00K derived: sum of 3 quarters · filed 2023-05-11 | $809.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $664.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $664.00K derived: sum of 2 quarters · filed 2023-03-20 | $663.00K derived: sum of 3 quarters · filed 2023-03-20 | $659.00K 10-K · filed 2023-03-20 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.00K derived: sum of 2 quarters · filed 2022-11-14 | -$5.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$5.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$4.00K 10-Q · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |